Faculty

Institution

Unit

Venue

Merle Diamond, MD

Rosalind Franklin University of Medicine and Science

Affiliations

Chicago Medical School

Clinical Sciences

Medical Education

School Of Chicago Medical

College of Health Professions

Department Of Biomedical Sciences

School Of Chicago Medical

Department Of Clinical Sciences

Department Of Emergency Medicine

Department Of Foundational Sciences And Humanities

Department Of Medicine

Illinois Board of Higher Education

Clinical Sciences

Internal Medicine

NoneMerle Diamond, Md is currently serving as a Chicago Medical School faculty at Rosalind Franklin University of Medicine And Science.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Merle Diamond, MD

Rosalind Franklin University of Medicine and Science

You can click a keyword to filter the displayed items

migraine neurology cluster headache pain management facial pain medicine pharmacology clinical trials pharmacotherapy neuropharmacology chronic pain treatment and prevention pain research pain medicine chronic migraine public health women's health symptom management neuroradiology complementary medicine neuropathic pain non-pharmacological interventions emergency care neuropathology intensive care emergency nursing neurologic intensive care acute pain clinical neurology emergency department neurodegenerative diseases preventive medicine obstetrics and gynaecology applied pharmacology neurorehabilitation intracranial pressure adverse events pain therapy local anesthetic pharmacology emergency department administration medication-overuse headache menstrual migraine migraine therapy emergency treatment migraine treatment child neurology canadian studies phytotherapy research disease prevention preventive cardiology health prevention neuropsychiatry primary investigation back pain symptomatic treatment pain syndromes neuromodulation (medicine) health technology assessment e-health service ehealth health information systems emergency management emergency medical services obstetrics treatment development high-risk pregnancies maternal-fetal medicine migraine prevalence preventive therapy disease burden united states migraine diagnosis medication overuse botulinum toxin type dual diagnosis subgroup analysis anesthesia trauma hospital medicine primary care world psychiatry neuroscience psychoneuroendocrinology critical care patient safety pediatric anesthesia medical sociology medical systems internal medicine translational psychiatry jama psychiatry alternative medicine medical history critical care clinic psychiatry clinical research translational medicine emergency medicine health care clinical epidemiology individualized medicine brain injury therapeutic approaches disaster medicine medical education health systems health policy integrative medicine translational research anesthesiology biological psychiatry health sciences medical ethics

Notable Scholarly Works

Notable Federal Grants

Collaborators

Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to Onabotulinumtoxina for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review. Pain and Therapy (2024)

medicinedrug safetypharmacologymigrainechronic migrainefacial painpharmacotherapyneuropharmacologyretrospective chart reviewcluster headacheclinical researchatogepant added

Eptinezumab Treatment Was Associated With Longer Interictal Headache/Migraine Periods Which Corresponded to Greater Improvements in Patient-Reported Quality of Life Measures. Journal of Neurology (2024)

neurologymedicinepain managementmigrainepatient-reported qualityfacial painpharmacotherapycluster headachepsychiatryclinical trialsside effectseptinezumab treatmentcomplementary medicinelife measures

Real-World Evidence of Adding Atogepant to Onabotulinumtoxina for Control of Chronic Migraine: A Retrospective Chart Review (P4-12.001). Neurology (2024)

neurologypharmacologymigrainechronic migrainefacial painneuropharmacologycluster headachereal-world evidenceneuroscienceadding atogepant

Safety and Tolerability Results of Atogepant for the Preventive Treatment of Episodic Migraine From a 40-Week, Open-Label Multicenter Extension of the Phase 3 Advance Trial. Cephalalgia (2023)

Brad C KleinRosa MiceliLawrence SevertPeter McAllisterLaszlo MechtlerJennifer McVigeMerle DiamondMichael J MarmuraHua GuoMichelle FinneganJoel M Trugman

neurologypain managementpharmacologymigraineopen-label multicenter extensionclinical trialspreventive treatmentepisodic migraineadvance trial

Evaluation of the Long-Term Safety and Tolerability of Oral Atogepant 60 Mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the Advance Trial (P3-2.001). Neurology (2022)

Brad KleinRosa MiceliLawrence SevertPeter McAllisterLaszlo MechtlerJennifer McVigeMerle DiamondMichael MarmuraHua GuoMichelle FinneganJoel Trugman

neurologymedicinepharmacologymulticenter extensionmigraineclinical trialslong-term safetyclinical neurologypreventive treatmentadvance trial

Preventive Migraine Treatment With Eptinezumab Reduced Acute Headache Medication and Headache Frequency to Below Diagnostic Thresholds in Patients With Chronic Migraine and Medication‐Overuse Headache. Headache The Journal of Head and Face Pain (2021)

Michael J. MarmuraHans‐Christoph DienerRobert P. CowanStewart J. TepperMerle L. DiamondAmaal J. StarlingJoe HirmanLahar MehtaThomas BrevigRoger Cady

neurologymigrainechronic migrainepreventive migraine treatmentheadache frequencydiagnostic thresholdsmedication-overuse headache

Efficacy, Tolerability, and Safety of Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication‐Overuse Headache: Subgroup Analysis of Promise‐2. Headache The Journal of Head and Face Pain (2020)

Hans‐Christoph DienerMichael J. MarmuraStewart J. TepperRobert CowanAmaal J. StarlingMerle L. DiamondJoe HirmanLahar MehtaThomas BrevigBjørn SperlingRoger Cady

neurologymedicinepain managementpharmacologymigrainechronic migrainepharmacotherapydual diagnosissubgroup analysismedication-overuse headache

Eptinezumab for the Prevention of Chronic Migraine: Efficacy and Safety Through 24 Weeks of Treatment in the Phase 3 Promise-2 (Prevention of Migraine via Intravenous Ald403 Safety and Efficacy–2) Study. The Journal of Headache and Pain (2020)

Stephen SilbersteinMerle DiamondNada A. HindiyehDavid M. BiondiRoger CadyJoe HirmanBrent AllanSusan PedersonBarbara SchaefflerJeff Smith

treatment and preventionneurologymedicinepharmacologymigrainechronic migrainepharmacotherapyclinical trials

Early Impact of Eptinezumab on the Health-Related Quality of Life (Hrqol) of Patients With Episodic or Chronic Migraine: Sf-36 Analysis Across the Spectrum of Migraine (P1.10-025). Neurology (2019)

neurologymedicinepain managementearly impactchronic painmigrainesymptom managementchronic migrainepharmacotherapycluster headachepsychiatryclinical trialstranslational psychiatrylife assessmentquality of lifesf-36 analysis

Approach to the Identification and Differentiation of Migraine.. PubMed (2018)

neurologyneuro-ophthalmologymigrainepain researchneuroradiologycluster headachepain mechanismneuroscienceepilepsy

1
2
3
4
5
6
10 / page